Skip to main content
Fig. 3 | Military Medical Research

Fig. 3

From: Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine

Fig. 3

Timeline of pancreatic cancer subtyping. The timeline of pancreatic cancer subtyping, together with the distinct classification approaches and the corresponding authors, including Collisson et al. [151], Moffitt et al. [28], Waddell et al. [152], Bailey et al. [153], Sivakumar et al. [154], Knudsen et al. [155], Wartenberg et al. [150], Puleo et al. [156], Karasinska et al. [157], Danilova et al. [149], Kalimuthu et al. [158], Law et al. [159], Chan-Seng-Yue et al. [31], and Huang et al. [29], are shown as indicated. KRAS GTPase KRas, PD-L1 programmed cell death ligand 1

Back to article page